GCP
ALBO

GSA Capital Partners’s Albireo Pharma Inc ALBO Stock Holding History

GSA Capital Partners’s Portfolio ALBO Stock Details ALBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-10,079
Closed -$200K – 1992
2022
Q2 		$200K Buy
+10,079
New +$266K 0.03% 1072
2022
Q1 		– Sell
-20,782
Closed -$484K – 1961
2021
Q4 		$484K Buy
20,782
+8,809
+74% +$234K 0.06% 622
2021
Q3 		$374K Buy
+11,973
New +$370K 0.04% 878
2020
Q2 		– Sell
-13,787
Closed -$226K – 1248
2020
Q1 		$226K Buy
+13,787
New +$303K 0.06% 679

Other funds holding ALBO

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

GSA Capital Partners's ALBO Position: Q3 2022 in Review

GSA Capital Partners sold out of Albireo Pharma Inc (ALBO) in Q3 2022, closing a stake of 10,079 shares — an estimated $200K sold.

GSA Capital Partners first reported a position in ALBO in Q1 2020 and held it in 4 quarters. The position peaked at $484K in Q4 2021. 108 funds tracked by Wall St. Rank hold ALBO as of Q3 2022.

  • GSA Capital Partners reported no remaining Albireo Pharma Inc position as of Q3 2022 after selling out during the quarter.
  • GSA Capital Partners sold 10,079 Albireo Pharma Inc shares in Q3 2022, an estimated $200K.
  • GSA Capital Partners first reported a position in Albireo Pharma Inc in Q1 2020 and held it in 4 quarters.
  • GSA Capital Partners's Albireo Pharma Inc position peaked at $484K in Q4 2021.
  • 108 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q3 2022.

Based on GSA Capital Partners's 13F filing for Q3 2022, filed 14 Nov 2022.